{"prompt": "['NET-PRO Protocol v1.3', 'April 2022', 'estimating PRRT to be administered in 10% of patients and further expecting a response rate of 60% in', 'the study, we would expect the PRRT group may have approximately 180 patients with complete HRQoL', 'data. Using a repeated measures design with 1 within-subject factor (time: baseline, 6 months, 12', 'months, and 18 months), the design achieves the following power (Table 5) to detect a time effect for', 'the corresponding mean change. Calculations are based on assuming an autocorrelation of 0.5 between', \"measurements, a standard deviation of 18, and using a Wilks' Lambda Approximate F Test with a 5%\", 'significance level. The power will be higher if PRRT administration amounts to more than 10% of the', 'prospective population.', 'Table 5: Alternative power for changes in EORTC QLQ-C30 within PRRT treated subgroup', 'MEAN CHANGE IN HRQOL OUTCOMES AT', 'DIFFERENCE IN MEAN HRQOL', 'POWER*', 'BASELINE, 6, 12 AND 18 MONTHS (RANGE 0-100)', '*', 'SCORE (OVER EACH TIME POINT)', '65, 62, 59, 56', '3-3-3', '100%', '65, 63, 61, 59', '2-2-2', '98.3%', '65, 63.5, 62, 60.5', '1.5-1.5-1.5', '84.3%', '* THE POWER APPLIES EQUALLY TO POSITIVE OR NEGATIVE SCORING SCALES.', '9.2.2. Aim 2', 'The primary objective of Aim 2 is to evaluate the effect of common treatment sequences on', 'progression-free survival. A lack of historical data on the frequency and number of different variations of', 'treatment sequences, and progression-free survival (PFS) differences by treatment and line of treatment', 'coupled with the likelihood treatment sequences will further differ between the 14 sites taking part in', 'this study make any realistic and meaningful sample size and power calculations impossible. Analyses', 'for this aim will be exploratory, and will leverage the use of time-varying covariates in combination with', 'the conditional Cox regression model proposed by Prentice, Williams, and Peterson (PWP) as a means', 'of', 'addressing the heterogeneity evidenced in the data. However, to put into perspective potential PFS', 'differences that may be detected between two treatments using purely hypothetical situations, the', 'below table summarizes power achieved for varying combinations of median PFS differences and', 'number of patients per treatment arm. Calculations are based on the following assumptions: 1:1', 'treatment allocation, 48 months of uniform accrual and 12 months of follow-up, no loss to follow-up or', 'switching treatments, unadjusted for confounders, and using the Lakatos approximation for a two-sided', 'log-rank test with a 5% significance level.', 'Table 6: Power determination for changes in median PFS', 'Median PFS', 'Treatment 1', 'Treatment 2 N Per Treatment Arm Power', '12 months', '24 months', '45', '0.79', '50', '0.83', '24 months', '36 months', '175', '0.80', '190', '0.83', '9.2.3. Aim 3', 'The primary objective of Aim 3 is to evaluate renal toxicity associated with the administration of PRRT as', 'measured by creatinine clearance loss over time. We are expecting 2 mL/min/1.73m\u00b2 annual decline in', 'creatinine clearance based on averaged long-term follow-up with the most common PRRT isotope 177-', 'Lu [34]. The repeated measures design with 180 subjects and 1 within-subject factor (time: baseline, 6', 'months, 12 months, and 18 months) achieves 100% power to detect creatinine clearance loss of 2', 'mL/min/1.73m\u00b2 by 6 months, 4 mL/min/1.73m\u00b2 by 12 months and 6 mL/min/1.73m\u00b2 by 18 months,', \"when the Wilks' Lambda approximate F test is used with a significance level of 0.05, and assuming an\", '38']['NET-PRO Protocol v1.3', 'April 2022', 'autocorrelation of 0.5 from one time point to the next and a standard deviation of 5 mL/min/1.73m\u00b2.', 'Should the standard deviation become unreasonably high in the order of 15 mL/min/1.73m\u00b2 our sample', 'size is large enough to achieve 99% power under the same parameter settings. In order to test', 'Bonferroni-corrected pairwise differences, the individual tests will achieve 99.6% power to detect a', 'clearance loss of 2 mL/min/1.73m\u00b2 between two time points. The Bonferroni-corrected tests will be set', 'at a significance level of 0.05/6.', '9.3. Addressing confounding', 'With a large, proposed sample size of approximately 3,000 patients, we will minimize the effects of', 'confounding on treatment effect estimates by adjusting for factors associated with treatment selection', 'within the context of multivariable models. Known and hypothesized factors associated with treatment', 'selection include but are not limited to the following: sociodemographic (age, sex, race, ethnicity,', 'marital status, income), health status (BMI, smoking history, comorbidities), disease (site, stage, grade,', 'nodal status), prior therapy use (PRRT, everolimus, sunitinib, liver-directed therapies, chemotherapy,', 'surgery), and patient-reported preferences, attitudes, beliefs and experience of care. Determination of', 'confounding factors that may warrant adjustment will be guided by the results from the multinomial', 'logistic regression models evaluating factors associated with selection of treatment regimens (Aim 2).', 'Furthermore, the use of time-dependent variables for treatment and potential confounders (where', 'appropriate) will minimize the effects of survivor treatment selection bias.', 'As a novel project aimed to evaluate the complex interplay between patient, disease, and treatment', 'factors on toxicity, HRQoL, and survival outcomes, the statistical analysis plan will be refined once', 'descriptive information from Aims 1 and 2 is available for consented patients. For example in Aim 3,', 'PRRT sits amongst a growing number of therapeutic options in metastatic well-differentiated NETs,', 'including pharmacological (i.e.: mTOR inhibitor everolimus and the tyrosine kinase inhibitor sunitinib),', 'hormonal and liver-directed therapies (i.e.: embolization (bland, chemo, radio)), and surgical', 'approaches. Therefore, we need to be mindful of this multimodal treatment algorithm wherein patients', 'may undergo a variety of treatment options at tumor progression(s).', '9.4. Addressing clustering of site', 'Patients seen at the same study site and by the same provider are at increased likelihood to be treated', 'more similarly. Random effects will be included in the multivariable models to account for clustering', 'within the 14 study sites and within provider (assuming a sufficient number of patients are seen by each', 'provider).', '9.5. Handling missing data', 'To minimize the effect of missing data on our ability to adjust for confounding factors, any clinical', 'variable found to be insufficiently populated in the CDM upon evaluation of submitted cohort', 'characterization data, will be abstracted via chart review for consented patients. Moreover, all 14', 'participating sites have agreed to provide tumor characteristics and NAACCR required variables i.e.:', 'tumor grade, stage, nodal status etc.) as important prognostic covariates. This tumor registry data will', 'be populated in each sites CDM tumor tables, and sites will have the opportunity to engage in data', 'quality curation using sample scripts developed by the GPC network informaticists (enhancing future', 'utilization of cancer registry variables in the CDM), see 10.2 below.', '39']\n\n###\n\n", "completion": "END"}